|281.71||-12.06||-4.11%||Vol 209.35K||1Y Perf -15.25%|
|Aug 9th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||347.00||Analyst Rating||Moderate Buy 1.78|
|Potential %||23.18||Finscreener Ranking||★+ 42.84|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★ 47.37|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★+ 61.72|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||38.80||Earnings Rating||Strong Buy|
|Market Cap||12.81B||Earnings Date||4th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|10 Years||1 213.33%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||1.09|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||280.11K|
|Avg. Monthly Volume||248.92K|
|Avg. Quarterly Volume||295.87K|
ABIOMED Inc. (NASDAQ: ABMD) stock closed at 281.71 per share at the end of the most recent trading day (a -4.11% change compared to the prior day closing price) with a volume of 209.35K shares and market capitalization of 12.81B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 1725 people. ABIOMED Inc. CEO is Michael R. Minogue.
The one-year performance of ABIOMED Inc. stock is -15.25%, while year-to-date (YTD) performance is -21.57%. ABMD stock has a five-year performance of 87.79%. Its 52-week range is between 219.845 and 379.295, which gives ABMD stock a 52-week price range ratio of 38.80%
ABIOMED Inc. currently has a PE ratio of 90.30, a price-to-book (PB) ratio of 8.14, a price-to-sale (PS) ratio of 15.40, a price to cashflow ratio of 43.10, a PEG ratio of 2.32, a ROA of 8.85%, a ROC of 7.12% and a ROE of 9.90%. The company’s profit margin is 20.26%, its EBITDA margin is 27.60%, and its revenue ttm is $779.17 Million , which makes it $17.08 revenue per share.
Of the last four earnings reports from ABIOMED Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.09 for the next earnings report. ABIOMED Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for ABIOMED Inc. is Moderate Buy (1.78), with a target price of $347, which is +23.18% compared to the current price. The earnings rating for ABIOMED Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ABIOMED Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ABIOMED Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.68, ATR14 : 9.74, CCI20 : 81.49, Chaikin Money Flow : 0.35, MACD : 9.47, Money Flow Index : 68.69, ROC : 3.15, RSI : 56.38, STOCH (14,3) : 72.63, STOCH RSI : 0.46, UO : 64.84, Williams %R : -27.37), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ABIOMED Inc. in the last 12-months were: David M. Weber (Option Excercise at a value of $233 279), David M. Weber (Sold 25 825 shares of value $8 288 310 ), Martin P. Sutter (Sold 40 642 shares of value $13 231 148 ), Michael R. Minogue (Option Excercise at a value of $80 840), Michael R. Minogue (Sold 3 492 shares of value $1 222 200 ), Paul G. Thomas (Sold 663 shares of value $219 301 ), Todd A. Trapp (Sold 3 000 shares of value $992 430 )
Sat, 30 Apr 2022 07:26 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Humana (HUM), Abiomed (ABMD) and Icon (ICLR)- TipRanks. All rights reserved.
Thu, 31 Mar 2022 06:55 GMT Abiomed (ABMD) Gets a Hold Rating from Leerink Partners- TipRanks. All rights reserved.
Tue, 29 Mar 2022 23:45 GMT Abiomed (ABMD) Gets a Hold Rating from BTIG- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.